Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$2.13.

  • Lyell Immunopharma's EPS (Basic) rose 3879.31% to -$2.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.32, marking a year-over-year increase of 17083.89%. This contributed to the annual value of -$1.28 for FY2024, which is 3763.14% down from last year.
  • Lyell Immunopharma's EPS (Basic) amounted to -$2.13 in Q3 2025, which was up 3879.31% from -$2.89 recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's EPS (Basic) registered a high of -$0.03 during Q4 2022, and its lowest value of -$3.59 during Q2 2024.
  • For the 5-year period, Lyell Immunopharma's EPS (Basic) averaged around -$1.05, with its median value being -$0.27 (2023).
  • As far as peak fluctuations go, Lyell Immunopharma's EPS (Basic) surged by 9221.79% in 2021, and later tumbled by 164000.0% in 2024.
  • Quarter analysis of 5 years shows Lyell Immunopharma's EPS (Basic) stood at -$0.18 in 2021, then skyrocketed by 83.33% to -$0.03 in 2022, then tumbled by 566.67% to -$0.2 in 2023, then tumbled by 275.22% to -$0.75 in 2024, then plummeted by 183.83% to -$2.13 in 2025.
  • Its EPS (Basic) stands at -$2.13 for Q3 2025, versus -$2.89 for Q2 2025 and -$0.18 for Q1 2025.